Evidence map›Paper›PMID 35528783›Full record

ArticleEuropean urology open science2022

Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register Study.

Tarik Almdalal, Pernilla Sundqvist, Ulrika Harmenberg, Mikael Hellström, Magnus Lindskog, Per Lindblad, Svan Lundstam, Börje Ljungberg

Open access · goldAbstract read
In one paragraph

Article in European urology open science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Tarik AlmdalalDepartment of Surgery and Urology, Eskilstuna Country Hospital, Eskilstuna, Sweden.
Pernilla SundqvistDepartment of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Ulrika HarmenbergDepartment of Oncology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
Mikael HellströmDepartment of Radiology, Sahlgrenska Academy/Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.
Magnus LindskogDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Per LindbladSchool of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Svan LundstamDepartment of Urology and Oncology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Börje LjungbergDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Örebro University · SEEskilstuna Municipality · SEKarolinska University Hospital · SESahlgrenska University Hospital · SEUmeå University · SEUniversity of Gothenburg · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: T1a renal cell carcinoma (RCC) is typically considered a curable disease, irrespective of the choice of local treatment modality. Objective: To identify factors associated with the risk of local and distant recurrence, and overall survival (OS) in patients with primary nonmetastatic clinical T1a RCC. Design setting and participants: A population-based nationwide register study of all 1935 patients with cT1a RCC, diagnosed during 2005-2012, identified through The National Swedish Kidney Cancer Register, was conducted. Outcome measurements and statistical analysis: Outcome variables were recurrence (local or distant) and OS. Possible explanatory variables included tumor size, RCC type, T stage, surgical technique, age, and gender. Associations with disease recurrence and OS were evaluated by multivariable regression and Cox multivariate analyses, respectively. Results and limitations: Among 1935 patients, 938 were treated with radical nephrectomy, 738 with partial nephrectomy, and 169 with ablative treatments, while 90 patients had no surgery. Seventy-eight (4%) patients were upstaged to pT3. Local or metastatic recurrences occurred in 145 (7.5%) patients, significantly more often after ablation (17.8%). The risk of recurrence was associated with tumor size, upstaging, and ablation. Larger tumor size, disease recurrence, and older age adversely affected OS, whereas partial nephrectomy and chromophobe RCC (chRCC) were associated with improved survival. Limitations include register design and a lack of comorbidity or performance status data. Conclusions: Upstaging and recurrence occurred, respectively, in 4.0% and 7.5% of patients with nonmetastatic RCCs ≤4 cm. Tumor size upstaging and ablation were associated with the risk for recurrence, while tumor size and recurrence were associated with decreased OS. Patients with chRCC and partial nephrectomy had prolonged OS in a real-world setting. Patient summary: We studied factors that may influence the risk of disease recurrence and overall survival, in a large nationwide patient cohort having nonmetastatic renal cell carcinoma ≤4 cm. Tumor size, tumor type, and treatment were associated with the risk of recurrence and overall death. Partial nephrectomy prolonged overall survival.

Indexed as

CryoablationOverall survivalPartial nephrectomyRadical nephrectomyRadiofrequency ablationRenal cell carcinomaRenal cell carcinoma typeT stageTumor size

Identifiers

PMID35528783
PMCPMC9068725
OpenAlexW4224862105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.